ArticleNeoplasia (New York, N.Y.)2018

Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.

Anna Wenger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.